Concord Biotech growth ratios

Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025
−12.1%+18.0%
−27.4%+17.3%
−35.2%+19.6%
−30.2%+20.6%
−30.2%+20.6%
+9.9%+19.6%
+11.2%+18.7%
+9.1%−7.9%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

CONCORDBIO₹1,230.60

Concord Biotech Ltd.

· Pharma & Health
₹ CrorePeersBIOCONDIVISLABCAPLIPOINTEMCUREBLUEJETERISGRANULESACUTAASMcap ₹12,874 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/09/2026
Revenue Growth——+18.0-12.1—
EBITDA Growth——+17.3-27.4—
EBIT Growth——+19.6-35.2—
Net Income Growth——+20.6-30.2—
EPS Growth——+20.6-30.2—
Total Assets Growth——+19.6+9.9—
Total Equity Growth——+18.7+11.2—
Cash from Operations Growth——-7.9+9.1—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.